• Home
  • Insight
  • Blog
  • Business
  • Entertainment
  • Health
  • Politics
  • Shop
    • Gift Shop
    • Value Shop
    • Store
    • Bargain Shop
    • Discount
  • Sports
  • Tech
  • Travel
  • USA
  • Video
  • World
    • Asia
    • Africa
    • South America
    • North America
    • Europe
    • Oceania
Tuesday, November 17, 2026
No Result
View All Result
Subscribe Now
  • Home
  • Insight
  • Blog
  • Business
  • Entertainment
  • Health
  • Politics
  • Shop
    • Gift Shop
    • Value Shop
    • Store
    • Bargain Shop
    • Discount
  • Sports
  • Tech
  • Travel
  • USA
    Stranded in Conflict: Palestinians Navigate the Tenuous Balance of War and Peace Amid Ceasefire Efforts

    Stranded in Conflict: Palestinians Navigate the Tenuous Balance of War and Peace Amid Ceasefire Efforts

    Trump Administration Revokes Pay Increase for Head Start Educators

    Trump Administration Revokes Pay Increase for Head Start Educators

    Unexpected Triumph: Gay Candidates Achieve Unforeseen Victories in Challenging Races

    Unexpected Triumph: Gay Candidates Achieve Unforeseen Victories in Challenging Races

    Microsoft Outlook Experiences Prolonged Outage Affecting Users Nationwide

    Microsoft Outlook Experiences Prolonged Outage Affecting Users Nationwide

    Gunfire Erupts in D.C.: Authorities Search for Suspect Amid Rising Concerns Over Public Safety

    Gunfire Erupts in D.C.: Authorities Search for Suspect Amid Rising Concerns Over Public Safety

    LAUSD Takes Strong Action Against Hate Speech Following Racial Slur Incidents

    LAUSD Takes Strong Action Against Hate Speech Following Racial Slur Incidents

    Beloved Former Los Angeles Times Columnist Steve Harvey Passes Away at 80

    Beloved Former Los Angeles Times Columnist Steve Harvey Passes Away at 80

    Exploring Diversity: ‘Ten Lives’ Showcases the Varied Economic Journeys of Americans

    Exploring Diversity: ‘Ten Lives’ Showcases the Varied Economic Journeys of Americans

    Philadelphia Eagles Facing Turmoil as Coach Nick Sirianni Addresses Controversy Over Gesture to Fans

    Philadelphia Eagles Facing Turmoil as Coach Nick Sirianni Addresses Controversy Over Gesture to Fans

  • Video
  • World
    • Asia
    • Africa
    • South America
    • North America
    • Europe
    • Oceania
The Insight Post
  • Home
  • Insight
  • Blog
  • Business
  • Entertainment
  • Health
  • Politics
  • Shop
    • Gift Shop
    • Value Shop
    • Store
    • Bargain Shop
    • Discount
  • Sports
  • Tech
  • Travel
  • USA
    Stranded in Conflict: Palestinians Navigate the Tenuous Balance of War and Peace Amid Ceasefire Efforts

    Stranded in Conflict: Palestinians Navigate the Tenuous Balance of War and Peace Amid Ceasefire Efforts

    Trump Administration Revokes Pay Increase for Head Start Educators

    Trump Administration Revokes Pay Increase for Head Start Educators

    Unexpected Triumph: Gay Candidates Achieve Unforeseen Victories in Challenging Races

    Unexpected Triumph: Gay Candidates Achieve Unforeseen Victories in Challenging Races

    Microsoft Outlook Experiences Prolonged Outage Affecting Users Nationwide

    Microsoft Outlook Experiences Prolonged Outage Affecting Users Nationwide

    Gunfire Erupts in D.C.: Authorities Search for Suspect Amid Rising Concerns Over Public Safety

    Gunfire Erupts in D.C.: Authorities Search for Suspect Amid Rising Concerns Over Public Safety

    LAUSD Takes Strong Action Against Hate Speech Following Racial Slur Incidents

    LAUSD Takes Strong Action Against Hate Speech Following Racial Slur Incidents

    Beloved Former Los Angeles Times Columnist Steve Harvey Passes Away at 80

    Beloved Former Los Angeles Times Columnist Steve Harvey Passes Away at 80

    Exploring Diversity: ‘Ten Lives’ Showcases the Varied Economic Journeys of Americans

    Exploring Diversity: ‘Ten Lives’ Showcases the Varied Economic Journeys of Americans

    Philadelphia Eagles Facing Turmoil as Coach Nick Sirianni Addresses Controversy Over Gesture to Fans

    Philadelphia Eagles Facing Turmoil as Coach Nick Sirianni Addresses Controversy Over Gesture to Fans

  • Video
  • World
    • Asia
    • Africa
    • South America
    • North America
    • Europe
    • Oceania
No Result
View All Result
No Result
View All Result
Home Health

F.D.A. Refuses to Review Moderna Flu Vaccine

by Theinsightpost
February 10, 2026
in Health
0 0
0
F.D.A. Refuses to Review Moderna Flu Vaccine

The vaccine maker Moderna said on Tuesday that the Food and Drug Administration had notified the company that the agency would not review its mRNA flu vaccine, the latest sign of federal health policy that has become hostile to vaccine development.

Dr. Vinay Prasad, the agency’s top vaccine regulator, rejected the company’s application for approval over a concern that Moderna’s clinical trial had compared its experimental vaccine against a product the agency did not consider the best on the market. People in the comparison group received Fluarix Quadrivalent, a flu vaccine sold by GSK.

Moderna had spent years and hundreds of millions of dollars testing its flu vaccine, enrolling 41,000 people and aimed at a market of adults ages 50 and older. The company concluded that its shot was superior to GSK’s product.

Stephen Hoge, the company’s president, said in an interview on Tuesday that the new flu vaccine was designed to be better tailored for a single nation than the ones that tended to be used by an entire hemisphere. He also said the F.D.A. had earlier indicated support for the company’s study plan.

“This refusal to start a review is all confusing, to say the least,” Mr. Hoge said, adding: “It is surprising, and we’re trying to understand what has changed.”

A spokesman for the Department of Health and Human Services, which oversees the F.D.A., said the agency did not comment on communications with individual applicants for drug approval.

Moderna said it had received what is known as a “refuse to file” letter from the agency, meaning that the company tried to submit an application for approval, but was dismissed. Such cursory rejections are unusual; the agency tends to complete a thorough review before denying approval.

Moderna said the agency’s letter did not cite any specific concerns about the product’s safety or effectiveness. A journal article published by company scientists last year concluded that the vaccine was safe. It reported that some of the company’s research showed that the vaccine had generated strong immune responses against both the A and B strains of the flu, though some results indicated that the vaccine seemed to work better against the A strain of the flu rather than the B strain.

A strains of the flu tend to cause more flu cases and more severe illness than B strains do.

This latest move by the F.D.A. reflects expansion of a new policy under Health Secretary Robert F. Kennedy Jr., who has repeatedly criticized the mRNA technology used most successfully against Covid and made by both Moderna and Pfizer. Recognized with a Nobel Prize in Physiology or Medicine in 2023, the technology instructs the body to produce a fragment of a virus that then sets off the body’s immune response.

But Mr. Kennedy has scuttled the use of mRNA in vaccines and canceled hundreds of millions of dollars in funding for research using the technology, claiming it is not safe or effective. During his first year as health secretary, he has quashed several projects involving the technology, including an effort by Moderna to develop a shot against bird flu.

Pfizer has been in a race with Moderna to develop an mRNA flu vaccine. However, Dr. Marty Makary, the F.D.A. commissioner, has alluded critically to Pfizer’s vaccine, saying in news media interviews that it failed to work in seniors in a clinical trial and suggesting it would not pass agency muster.

Moderna spent years on the studies for a vaccine that was meant to improve on egg-based and other methods to combat the flu, allowing nations to specifically select the strain they hoped to target.

Mr. Hoge said the company met with the F.D.A. about the study and understood that the decision of which vaccine to use in comparison would be acceptable, albeit a “review issue,” he recounted. He said the company had requested an additional meeting with the agency about its decision to reject the application.

Mr. Hoge said Blackstone, the private equity company, had invested $750 million in the development of Moderna’s flu shot, in addition to the vaccine maker’s own support for the large clinical trial.

No country has approved an mRNA flu vaccine, although Mr. Hoge said Moderna’s product was being reviewed in Europe, Canada and Australia.

Dr. Prasad’s letter to Moderna said the reason for the refusal was that the company had not run an “adequate and well-controlled” study but had compared its product with a flu vaccine that “does not reflect the best-available standard of care.”

In recent months, Dr. Prasad has held drug companies to standards that were different from what they were expecting based on previous agency guidance, generating backlash from the biotech and pharmaceutical industries. In November, a long list of biotech investors and chief executives wrote a letter of concern about “decisional volatility” and turmoil at the F.D.A.

Dr. Makary has defended Dr. Prasad’s decisions and said the agency’s drug approvals last year were in line with recent years.

In a large clinical trial, Pfizer’s experimental mRNA vaccine against the flu was found to be at least as good as a comparison product against A strains of the flu, but not against B strains. Funded by Pfizer, the study compared the company’s experimental vaccine against Fluzone, a shot on the market sold by Sanofi.

In an interview on “Fox & Friends” in November, Dr. Makary criticized Pfizer’s data, though he did not name the company. “We’re not just going to rubber-stamp new products that don’t work, that fail in a clinical trial,” he said. “It makes a mockery of science if we’re just going to rubber-stamp things with no data.”

In another interview the next month with NPR, Dr. Makary suggested that Pfizer’s vaccine did not meet the agency’s criteria for approval. “I personally like mRNA technology. But this mRNA flu shot in its randomized control trial in seniors failed. It showed no benefit,” he said.

He added: “Well, we basically said, We’re not interested in approving a drug that has failed in its Phase 3 randomized trial.”

Pfizer did not immediately return a request for comment on Tuesday.

Perhaps no vaccine developer has been harder hit than Moderna, as federal health officials have turned against mRNA technology and some vaccines. Demand for the company’s Covid vaccine has declined considerably, after generating huge sales at the height of the pandemic. The F.D.A. also narrowed approval of Covid shots for the season that began last fall. Moderna’s stock has plummeted by more than 90 percent since its peak in August 2021.

Moderna has said it is halting plans for late-stage studies of some experimental vaccines aimed at preventing infectious diseases and infections that lurk in the body. Late-stage studies of Moderna’s experimental cancer vaccines are expected to continue unimpeded.

ShareTweetSend
Previous Post

The Christian Influencers Protecting Their Peace

Next Post

There’s New Blood in the Old-Money Upper East Side Gallery Scene

Related News

VA Partners with TEFCA to Enhance Health Information Sharing for Veterans
Health

VA Partners with TEFCA to Enhance Health Information Sharing for Veterans

November 14, 2026
Native Americans Exempt from Medicaid Work Requirements, Yet Risk Losing Coverage Remains
Health

Native Americans Exempt from Medicaid Work Requirements, Yet Risk Losing Coverage Remains

November 13, 2026
Paving the Path: Strategies for Democrats to Lead the Next Wave of Immigration Reform
Health

Paving the Path: Strategies for Democrats to Lead the Next Wave of Immigration Reform

November 13, 2026
ONC and CMS Unveil Groundbreaking Initiative to Enhance Electronic Prior Authorization Testing
Health

ONC and CMS Unveil Groundbreaking Initiative to Enhance Electronic Prior Authorization Testing

November 12, 2026
Next Post
There’s New Blood in the Old-Money Upper East Side Gallery Scene

There’s New Blood in the Old-Money Upper East Side Gallery Scene

Discussion about this post

Subscribe To Our Newsletters

    Customer Support


    1251 Wilcrest Drive
    Houston, Texas
    77042 USA
    Call-832.795.1420
    e-mail – news@theinsightpost.com

    Subscribe To Our Newsletters

      Categories

      • Africa
      • Africa-East
      • African Sports
      • American Sports
      • Arts
      • Asia
      • Australia
      • Business
      • Business Asia
      • Business- Africa
      • Canada
      • Defense
      • Education
      • Egypt
      • Energy
      • Entertainment
      • Europe
      • European Soccer
      • Finance
      • Germany
      • Ghana
      • Health
      • Insight
      • International
      • Investing
      • Japan
      • Latest Headlines
      • Life & Living
      • Markets
      • Mobile
      • Movies
      • New Zealand
      • Nigeria
      • Politics
      • Scholarships
      • Science
      • South Africa
      • South America
      • Sports
      • Tech
      • Travel
      • Travel-Africa
      • UK
      • USA
      • Weather
      • World
      No Result
      View All Result

      Recent News

      Gators Shock Wildcats 21-14 in Thrilling Upset Amid Rollercoaster Season

      Gators Shock Wildcats 21-14 in Thrilling Upset Amid Rollercoaster Season

      November 15, 2026
      Government Announces Historic  Billion Investment in Energy Infrastructure Development

      Government Announces Historic $2 Billion Investment in Energy Infrastructure Development

      November 15, 2026
      Notre Dame Postgame Insights: Dive into Superchats with Westwood One Sports

      Notre Dame Postgame Insights: Dive into Superchats with Westwood One Sports

      November 15, 2026
      Transform Your Laptop Setup with These 5 Affordable Accessories

      Transform Your Laptop Setup with These 5 Affordable Accessories

      November 15, 2026
      • Home
      • Advertise With Us
      • About Us
      • Corporate
      • Consumer Rewards
      • Forum
      • Privacy Policy
      • Social Trends

      Theinsightpost ©2026 | All Rights Reserved. Theinsightpost is an Elnegy LLC company, registered in Texas, USA

      Welcome Back!

      Login to your account below

      Forgotten Password?

      Retrieve your password

      Please enter your username or email address to reset your password.

      Log In

      Add New Playlist

      We are using cookies to give you the best experience on our website.

      You can find out more about which cookies we are using or switch them off in .

      No Result
      View All Result
      • Home
      • Insight
      • Blog
      • Business
      • Entertainment
      • Health
      • Politics
      • Shop
        • Gift Shop
        • Value Shop
        • Store
        • Bargain Shop
        • Discount
      • Sports
      • Tech
      • Travel
      • USA
      • Video
      • World
        • Asia
        • Africa
        • South America
        • North America
        • Europe
        • Oceania

      Theinsightpost ©2026 | All Rights Reserved. Theinsightpost is an Elnegy LLC company, registered in Texas, USA

      The Insight Post
      Powered by  GDPR Cookie Compliance
      Privacy Overview

      This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.

      Strictly Necessary Cookies

      Strictly Necessary Cookie should be enabled at all times so that we can save your preferences for cookie settings.

      Cookie Policy

      More information about our Cookie Policy